GI symptoms in axSpA -Cohort of 370 pts with axSpAfrom New Zealand -Elevated fecal calprotectin ➡️ positive correlat

Tweet Author

Tweet Content

GI symptoms in axSpA -Cohort of 370 pts with axSpAfrom New Zealand -Elevated fecal calprotectin ➡️ positive correlation with GI symptoms and high disease activity -Bowel symptoms associated with reduced quality of life. -Use of TNFi improved bowel symptoms over time. https://t.co/wA37G3HWyi

Links

https://x.com/AdelaCastro222/status/1932822048901841257/photo/1

IL-17 inhibition for PMR?In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperfo

Tweet Author

drdavidliew

Tweet Content

IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1

Links

https://x.com/drdavidliew/status/1932822621634109638/photo/1

MONITOR PsA 200+ pts secondary care "real-life" cohort 65 treated w/ combi csDMARDs 48weeks outcome and 96 weeks 49% bi

Tweet Author

AurelieRheumo

Tweet Content

MONITOR PsA 200+ pts secondary care "real-life" cohort 65 treated w/ combi csDMARDs 48weeks outcome and 96 weeks 49% bioDMARDs, 29% retention and 23% deescalation to 1 csDMARD ‼️reasons for discontinuation was AEs in 60% cases not inefficacy Caveat: analysis not adjusted for https://t.co/L8EczgZTpP

Links

https://x.com/AurelieRheumo/status/1932823234577125636/photo/1

A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societ

Tweet Author

DrMiniDey

Tweet Content

A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societal costs & +0.05 QALYs over 12m vs usual care (95% probability at €20k/QALY). Results suggest cost-effective compared to usual care. @RheumNow #EULAR2025 #OP0007

RA polygenic risk ≠ MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI

Tweet Author

DrMiniDey

Tweet Content

RA polygenic risk ≠ MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI incidence. Familial clustering of RA & MI likely driven by non-genetic factors. Traditional CV risk still key in RA care. @RheumNow #EULAR2025 #OP0072 https://t.co/KN6Dg0ekt2

Links

https://x.com/DrMiniDey/status/1932824645662552347/photo/1

Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant i

Tweet Author

AdelaCastro222

Tweet Content

Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant improvement on DAI measures as well. -Fully humanized IgG4 mab may last longer in system and possible less ADAs. Abstract #OP0102 #EULAR2025 @RheumNow https://t.co/vyNHZ9ssFt

Links

https://x.com/AdelaCastro222/status/1932824996671373641/photo/1

📊 POS0574 @rheumnow #EULAR2025Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA

Tweet Author

JihaRheum

Tweet Content

📊 POS0574 @rheumnow #EULAR2025 Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA. ✔️ 57% had no tender/swollen joints at Year 5 ✔️ PASI90 in ~48% ✔️ Stable low TJC, SJC & PtGA Durability confirmed even in prior biologic users. https://t.co/eNpboTRRu3

Links

https://x.com/JihaRheum/status/1932800240756650358/photo/1

Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer

Tweet Author

AurelieRheumo

Tweet Content

Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer Hx -CV comorbidities -Chronic use of NSAID or GCs Protective: Regular participation in leisure activities #POS0030 @RheumNow #EULAR2025 https://t.co/qNHQoHCb80

Links

https://x.com/AurelieRheumo/status/1932801565401784443/photo/1

REGULATE-RA and REGULATE-HS FIH CAR-Treg targeting Cit-P Refractory RA (at least 3 MoA) 3 RA pts dosed & 3 Hidraden

Tweet Author

AurelieRheumo

Tweet Content

REGULATE-RA and REGULATE-HS FIH CAR-Treg targeting Cit-P Refractory RA (at least 3 MoA) 3 RA pts dosed & 3 Hidradenitis Suppurativa 0 SAE, DLTs or CRS Grade 1 TEAs mainly, one Grade 2 Efficacy and PD analysis ongoing #POS0034 #EULAR2025 @RheumNow https://t.co/Glw3NNFepF

Links

https://x.com/AurelieRheumo/status/1932806933473345695/photo/1

If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden po

Tweet Author

drdavidliew

Tweet Content

If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden post-hoc trial: these patients don’t do worse than those who never get off drug. Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/QDxNRPN9f1

Links

https://x.com/drdavidliew/status/1932807087840457182/photo/1

Topics

GI symptoms in axSpA -Cohort of 370 pts with axSpAfrom New Zealand -Elevated fecal calprotectin ➡️ positive correlat

IL-17 inhibition for PMR?In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperfo

MONITOR PsA 200+ pts secondary care "real-life" cohort 65 treated w/ combi csDMARDs 48weeks outcome and 96 weeks 49% bi

A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societ

RA polygenic risk ≠ MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI

Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant i

📊 POS0574 @rheumnow #EULAR2025Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA

Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer

REGULATE-RA and REGULATE-HS FIH CAR-Treg targeting Cit-P Refractory RA (at least 3 MoA) 3 RA pts dosed & 3 Hidraden

If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden po

Do you get our email newsletter?